Background: Late-onset Alzheimer disease (LOAD) is a common disorder with a substantial genetic component. We postulate that many disease susceptibility variants act by altering gene expression levels.
sion levels in the brain. If correct, such variants would associate with both AD risk and brain gene expression levels.
We performed a pilot study using cerebellar gene expression levels of 12 LOAD candidate genes and their cis-single nucleotide polymorphism (SNP) genotypes extracted from our LOAD GWAS. 14 Most of these 12 messenger RNAs (mRNAs) encode proteins that are likely to be involved in neurodegeneration.
We identified 3 IDE cis-SNP/transcript associations with study-wide significance. One of these cis-SNPs showed an association with genome-wide significance. This SNP also associated significantly with LOAD risk. Our findings suggest that joint analysis of transcriptome and disease risk with genome data could identify candidate functional variants that influence disease risk by influencing gene expression. The use of brain expression endophenotypes may be a potentially powerful approach in uncovering the genetics of neurologic diseases like LOAD.
METHODS Subjects and samples for genotyping. For our GWAS, we genotyped 970 LOAD cases and 1,495 controls from 3 series, collected at Mayo Clinic, Jacksonville, FL (JS_60 -80 series), Mayo Clinic, Rochester, MN (RS_60 -80 series), and an autopsy-based series (AUT_60 -80). The LOAD GWAS subjects had an age at diagnosis/entry of 60 -80 years. Four additional series were genotyped for the most significant IDE cis-SNP, rs7910977. Three of these additional series were collected at Mayo Clinic, Jacksonville, FL (JS_80ϩ), Mayo Clinic, Rochester, MN (RS_80ϩ), and an autopsy series (AUT_80ϩ). The fourth additional series was from the National Cell Repository for AD (NCRAD). All subjects are white Americans (appendix e-1: Methods and table e-1 on the Neurology ® Web site at www.neurology.org).
Standard protocol approvals, registrations, and patient consents. This study was approved by the appropriate institutional review board and appropriate informed consent was obtained from all participants. LOAD GWAS. The LOAD GWAS genotypes were generated using Illumina's HumanHap300-Duo Genotyping BeadChips analyzed with an Illumina BeadLab Station (Illumina, San Diego, CA) at the Mayo Clinic Genotyping Shared Resource according to the manufacturer's protocols. GWAS quality control is discussed in appendix e-1: Methods.
cis-SNP/mRNA expression level associations for 12 LOAD candidate genes. Autopsy series for mRNA expression analyses.
A total of 200 autopsy-confirmed LOAD subjects from the AUT_60 -80 series of our GWAS underwent cerebellar gene expression level measurements. TaqMan ® Arrays 15, 16 were used for the gene expression studies (appendix e-1: Methods).
For follow-up analysis of the most significant IDE cis-SNP rs7910977/transcript association, we measured cerebellar IDE mRNA levels in 3 additional groups composed of autopsy-confirmed LOAD subjects with age at diagnosis Ն80 years, control subjects with age at entry of 60 -80 years, and control subjects with age at entry Ն80 years. All control subjects had Braak scores of 2.5 or lower, but many had brain pathology unrelated to AD. Selection of 12 LOAD candidate genes for expression studies. We identified cis-SNPs for 12 candidate genes that were genotyped in our LOAD GWAS (table e-2) . We define cis-SNPs as variants that either reside within each gene or in its flanking regions (Ϯ100 kb). There were 582 cis-SNPs in our LOAD GWAS, of which 564 remained for analysis after the quality control exclusions (appendix e-1).
Statistical analysis. 12 LOAD candidate gene cis-SNP/
mRNA expression level association analyses. Statistical analyses were carried out using PLINK, 17 SPlus 8.0, or StatsDirect (v. 2.6.5). The ⌬C T values representing brain expression levels of each gene were utilized as endophenotypes. All cis-SNPs were analyzed for association with the expression levels of the corresponding gene using an additive linear regression model, that included minor allele dosage (0, 1, 2) as the primary independent variable, and APOE ⑀4 dosage (0, 1, 2), age at diagnosis/ entry, and gender as covariates. We tested and corrected for population stratification using EIGENSTRAT 18 (appendix e-1: Methods).
IDE cis-SNPs/LOAD risk association analyses. Given that IDE cis-SNPs had the strongest association with expression levels, we tested for their associations with LOAD risk using PLINK. 17 We performed logistic regression analyses using a logadditive model for the minor allele (0, 1, or 2 copies), while including covariates for APOE ⑀4 dosage (0, 1, 2), age at diagnosis/entry, sex, and series. All IDE cis-SNPs/LOAD risk associations were tested in the 3 LOAD GWAS series. The most significant SNP, rs7910977, was also assessed in the 4 additional series described above. To assess the potential that there were differential SNP associations by series, we used logistic regression models to test for a significant series ϫ genotype interaction.
RESULTS Twelve LOAD candidate gene cis-SNP/
transcript associations. Of the 619 cis-SNP/transcript associations tested in 200 subjects with autopsyconfirmed LOAD with age at diagnosis of 60 -80 years, only 3 IDE cis-SNPs achieved p Ͻ 0.05 after study-wide Bonferroni correction: rs7910977, rs1999763, and rs10882088. When q-values [19] [20] [21] are obtained, only the top 3 IDE SNPs had a greater than 95% probability of being true positives. Four (3 IDE, 1 CTNNA3), 9 (7 IDE, 1 CTNNA3, 1 APP), and 15 (10 IDE, 3 CTNNA3, 1 APP, 1 GRN) cis-SNPs had q-values less than 0.1, 0.33, and 0.5. Some of these suggestive results may be genuine associations that could be replicated in a larger study. In this article, we focus on the IDE cis-SNP/transcript associations that were highly significant. IDE cis-SNPs associate significantly with IDE expression levels. IDE cis-SNP rs7910977 is 4.2 kb from the 3Ј end, rs10882088 is 34.8 kb from the 5Ј end, and rs1999763 is within the second intron of IDE. The most significantly associated SNP, rs7910977, had a p value of 2.7 ϫ 10 Ϫ8 , which would be signif-icant even at genome-wide level. IDE expression level in minor allele carriers of each cis-SNP is roughly twice that in major homozygotes (table 1, figure 1). Adjustment for population stratification had essentially no effect on the IDE cis-SNP/transcript associations (appendix e-1: Results, table e-3).
To follow up the most significant IDE cis-SNP rs7910977/IDE transcript association observed in the subjects with LOAD from our GWAS, we measured cerebellar IDE mRNA expression and genotyped rs7910977 in 3 additional groups from the autopsy series, collectively composed of 389 subjects (table 2). In each of the additional groups tested, rs7910977 minor allele was associated with elevated IDE transcript levels (table 2), but the fold expression level difference in each group was smaller than that in the initial 60 -80 year AD group (2.05-fold, 95% confidence interval [CI] 1.6 -2.62). When all 3 follow-up groups were combined, the fold difference was 1.24 (95% CI 0.99 -1.54, p ϭ 0.058). When the data from all 4 groups were combined, the fold difference associated with each copy of the minor allele of rs7910977 was 1.45 (95% CI 1.22-1.71) and the association continued to be highly significant (p ϭ 2.6 ϫ 10 Ϫ5 ).
IDE cis-SNP/LOAD risk associations are less robust
than IDE expression level associations. We tested for association with LOAD risk using the 24 IDE cis-SNPs from our LOAD GWAS (table e-4). The logistic regression p values for the top 3 IDE expression cis-SNPs are 0.0047, 0.23, and 0.93 for the rs7910977, rs1999763, and rs10882088 SNPs (table  3) . While only rs7910977 demonstrated significant association with AD, the odds ratio (OR) estimates for all 3 IDE SNPs indicate a protective effect for the minor allele. These results are biologically consistent with the higher IDE expression levels associating with the minor alleles of these SNPs.
IDE cis-SNP rs7910977 shows consistent association
with LOAD risk in 7 independent series. In addition to the 3 LOAD GWAS series, we genotyped the rs7910977 SNP in 4 more case-control series (figure 2 and table e-5). The OR estimates for each of the series are protective, though only JS_60 -80 series achieves significance. The OR estimate for the rs7910977 SNP minor allele in the combined series is 0.81 (95% CI 0.70 -0.94, p ϭ 0.0046). This LOAD association was obtained in 2,280 patients with AD and 2,396 controls, whereas the genomewide significant rs7910977/IDE expression association was obtained in 176 subjects. The strength of association for LOAD risk is much less robust than that for the IDE expression phenotype. Series with younger ages at diagnosis/entry (JS_60 -80, RS_60 -80, AUT_60 -80) appear to harbor a stronger effect for the rs7910977/AD association compared to the older series (JS_80ϩ, RS_80ϩ, AUT_80ϩ). However, the comparison of heterogeneity by series on the rs7910977/AD association did not reach significance (data not shown).
DISCUSSION Functional variants that influence disease risk by influencing gene expression may have a substantial contribution to the genetics of common diseases. 9 Identification of variants that associate both with AD and gene expression levels will provide important supportive evidence for the role of expression-SNPs in conferring disease risk. To test this hypothesis, we performed a pilot study, where we tested 564 cis-SNPs from our LOAD GWAS 14 for association with the transcripts of 12 LOAD candidate genes measured in the cerebellum of subjects with LOAD. We identified 3 IDE cis-SNPs that reached study-wide significance. The IDE cis-SNP rs7910977/transcript associations achieved genomewide significance even in the small number of samples that were analyzed (n ϭ 176). In these samples, IDE mRNA levels in minor allele carriers of rs7910977 were approximately twice those in noncarriers. This SNP also associated ( p ϭ 0.0046) with reduced risk of LOAD when 2,280 LOAD cases and 2,396 controls from 7 independent series were collectively analyzed. In a separate study (M. Allen, personal communication), the association of rs7910977 with plasma amyloid ß 40 (Aß40) and Aß42 was analyzed in 949 individuals from Vis and 930 individuals from Korcula, 2 isolated populations recently analyzed for multiple disease-related traits using genome-wide scans. [22] [23] [24] In the combined data from these 1,879 subjects, rs7910977 showed association with reduced Aß40 (␤ Ϯ SE ϭ Ϫ0.124 Ϯ 0.05, p ϭ 0.011) and suggestive association with reduced plasma Aß42 levels (meta-analysis ␤ Ϯ SE ϭ Ϫ0.07 Ϯ 0.05, p ϭ 0.18). Thus, rs7910977 showed strong association with elevated IDE expression and reduced risk of LOAD in the current study and, in a separate study, it showed significant association with reduced levels of A␤, a substrate of IDE that is implicated in LOAD pathogenesis.
The IDE cis-SNP rs7910977 is in complete LD with rs6583817, which resides in an evolutionarily conserved region of IDE in intron 12. This region is expected to harbor putative transcription factor binding sites. Furthermore, the minor allele of rs6583817 (tagged by the minor allele of rs7910977) is predicted to alter the binding of transcription factors in a way that would increase expression of IDE mRNA (appendix e-1: Results).
In this study, we analyzed mRNAs in LOAD brain tissue obtained at autopsy to improve detection of brain-specific cis-SNP/transcript associations that would go undetected in peripheral tissues or lymphoblastoid cell lines. Because LOAD causes profound neuronal cell loss and astrogliosis that may alter mRNA levels in affected regions, mRNAs were measured in the cerebellum, which is largely unaffected by LOAD pathology. Since our goal was to identify expression differences due to genetic effects rather than those that occur as a result of neurodegeneration or neuronal loss, cerebellar tissue was chosen for RNA extractions. Our search for cis-SNP/transcript associations relevant to LOAD in cerebellum presupposes that at least some LOAD SNPs will influence gene expression similarly in brain regions both affected and unaffected by AD pathology. Some genetic variants may alter expression similarly in affected and unaffected brain regions and even in peripheral tissues and lymphoblastoid cell lines. Abbreviations: AD ϭ Alzheimer disease; CI ϭ confidence interval. a IDE rs7910977 SNP/cerebellar IDE mRNA expression level associations were evaluated in 3 follow-up groups besides the initial autopsy-confirmed late-onset Alzheimer disease subjects with age at diagnosis 60 -80 years (60 -80 AD). The multivariable linear regression model depicted in table 1 was used in all analyses except for that in the 1) combined follow-up groups and 2) combined all groups, which included group effects, in addition to the other covariates. It is possible, however, that some SNPs will only affect expression in brain regions affected by AD pathology.
To fully exploit mRNA levels as LOAD endophenotypes it will, therefore, be important to search for strong cis-SNP/transcript associations in a variety of brain regions, tissues, and cell lines from both LOAD and unaffected control subjects. Our results suggest that the rs7910977/IDE transcript association may be context dependent. Rs7910977 was consistently associated with elevated IDE transcript in all groups tested (table 2). In our combined data, each copy of the minor allele of rs7910977 was associated with a 1.45-fold elevation in IDE transcript level ( p ϭ 2.6 ϫ 10 Ϫ5 ), but the elevation of 2.05-fold observed initially in the 60 -80 year AD group was considerably greater than that observed in any of the 3 follow-up groups (80ϩ AD, 60 -80 controls, 80ϩ controls).
Our strong association with gene expression levels obtained using Ͻ200 subjects that is biologically congruent with the AD risk association in Ͼ4,500 subjects provides evidence that 1) joint analysis of disease risk and brain gene expression levels may lead to the identification of candidate functional AD variants and 2) the use of gene expression endophenotype may be a more powerful approach than the use of the disease phenotype, likely due to increased underlying genetic homogeneity of the endophenotype and the increased statistical power of the quantitative phenotype. In fact, our expression analyses would have had greater than 99% power to detect an association at genome-wide significance, even if the SNP association led to a 1.5-fold change rather than the twofold differences that were observed. On the other hand, even with the thousands of cases and controls in the LOAD/SNP association analyses, we only would have had 47% power to detect the observed association at genomewide significance. Indeed, the LOAD GWAS reported to date, 14, [25] [26] [27] [28] [29] [30] [31] including our study, utilize thousands of subjects to achieve genome-wide significance, whereas the expression endophenotype approach has led to results at this level of significance utilizing hundreds of subjects. [11] [12] [13] 32, 33 Thus, the expression GWAS approach may be a more powerful strategy to identify the genetic underpinnings of common, complex diseases.
We suggest the use of the expression GWAS as a complementary approach to the more traditional disease GWAS. This is because not all functional variants are expected to influence gene expression and the disease GWAS approach screens the whole genome for risk variants regardless of the underlying biology. Furthermore, the disease GWAS, in conjunction with the expression GWAS, will allow the cross-validation of the association results from both approaches, thereby leading to the identification of a set of plausible candidate functional disease variants influencing gene expression.
Until recently, APOE was the only locus robustly associated with LOAD. 3 Additional promising genes that have weaker association with LOAD are now being identified as GWAS are performed on case-control series of sufficient size. Among these are SORL1, 34 GAB2, 26 and PCDH11X. 14 With the recent publication of 2 powerful genome-wide association studies, 3 more susceptibility genes have been identified: CLU, PICALM, and CR1. 30, 31 Our results suggest that analysis of cis-SNPs in these genes for association with their transcript levels in brain may lead to a better understanding of their mechanism of action.
IDE also degrades A␤ and influences its level in the brain. [35] [36] [37] IDE is also located near regions of LOAD linkage on chromosome 10q, 38, 39 making it an excellent LOAD candidate gene. This has prompted at least 19 studies investigating the association of IDE variants with LOAD and its endophenotypes. 40 Some of these studies showed highly significant association, and others did not. In addition, no published GWAS on LOAD 14,25-31 has identified variants within IDE as risk variants for LOAD at a level of significance that remained noteworthy after correction for multiple testing. All of these findings reinforce our conclusion that IDE is a LOAD gene with variants that have strong effects on IDE expression and Odds ratio plots of Alzheimer disease association with rs7910977 SNP in 7 late-onset Alzheimer disease casecontrol series
The odds ratio (OR) and 95% confidence interval (CI) of Alzheimer disease (AD) association for the rs7910977 SNP were obtained using a logistic regression approach using age at diagnosis/entry, APOE 4 genotype, and sex as covariates. The series names are shown to the left and the OR estimates (95% CI) to the right of each series. In the combined analysis, series effects were included as covariates. We also formally tested for a series effect by including "series ϫ genotype" variables in the model and determined no significant evidence for a series ϫ genotype effect.
weaker effects on LOAD risk. By chance, the weak association of IDE variants with LOAD risk occasionally reaches statistical significance in some case-control studies; however, the size of the previously published casecontrol series lacks the power needed to show significant association consistently. The strong IDE cis-SNP/transcript association that we observed was not evident in a study 32 which investigated associations between 366,140 SNPs and 14,078 transcripts from the cerebral cortex of 193 neuropathologically normal subjects. It is important to emphasize that IDE expression level data were available for only 70 of the 193 subjects in this study, making it considerably less powerful than our dataset (178 samples) to detect IDE cis-SNP/transcript associations. Other reasons for this discrepancy may be related to differences in the SNPs tested in the 2 studies, the brain region studied, the method of mRNA quantification, or the fact that we analyzed LOAD brains. This group recently reported their analysis of brain transcriptome levels from 176 cases with pathologic diagnosis of AD and 188 neuropathologically normal subjects for 8,650 transcripts. 33 Given that IDE was not among the 8,650 transcripts reported, we are unable to compare our results on this gene with this study.
Recent GWAS of transcripts from lymphoblastoid cell lines [11] [12] [13] and human cerebral cortex 32, 33 indicate that many cis-SNPs show strong association that achieves genome-wide significance when hundreds of samples are analyzed. These studies identifying many genes with strong cis-SNP/transcript associations fit well with our finding that 1 of 564 cis-SNPs tested for association with 12 transcripts showed genomewide significance. Thus our results support the concept that genes with strong cis-SNP/transcript associations can be analyzed effectively for association with disease using the most significant cis-SNP from each gene. Because the number of SNPs with such strong, functionally meaningful associations will be small relative to the number of SNPs tested in a typical GWAS, analysis for association with disease will require less correction for multiple testing and have greater power to detect weak disease associations than a typical GWAS. It should be possible to identify these SNPs relatively efficiently, for testing in follow-up studies of large case control series, by performing GWAS of the whole transcriptome in affected and unaffected brain regions from several hundred LOAD cases and controls. Our results provide strong evidence that IDE is a LOAD gene with variants that reduce risk of LOAD by increasing IDE expression that would thereby reduce A␤. More generally, they suggest that the use of brain mRNA levels as endophenotypes in LOAD GWAS may be a powerful way to identify LOAD susceptibility alleles.
